As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Kup ten ebook, a 1 kolejny otrzymasz GRATIS!
Format PDF ● Strony 444 ● ISBN 9781466579705 ● Wydawca CRC Press ● Opublikowany 2013 ● Do pobrania 6 czasy ● Waluta EUR ● ID 2715426 ● Ochrona przed kopiowaniem Adobe DRM
Wymaga czytnika ebooków obsługującego DRM